In short
This article discusses a groundbreaking clinical trial investigating the use of AZD8421, a new drug being tested for treating advanced or metastatic solid tumors. The study focuses on patients with ER+HER2- advanced breast cancer and high-grade serous ovarian cancer. The trial aims to assess the safety, effectiveness, and how the body processes AZD8421 when used alone or in combination with other cancer drugs.
At a glance
- Study Type
- Phase I/IIa, first-in-human, open-label, dose escalation and expansion study
- Drug
- AZD8421 (CDK2 inhibitor)
- Target Conditions
- ER+HER2- advanced breast cancer, high-grade serous ovarian cancer
- Study Arms
- 1. AZD8421 monotherapy 2. AZD8421 with camizestrant and abemaciclib 3. AZD8421 with camizestrant and ribociclib 4. AZD8421 with camizestrant and palbociclib
- Primary Outcomes
- Safety and tolerability (DLTs, AEs/SAEs, lab parameters, discontinuation rate)
- Secondary Outcomes
- Efficacy (ORR, DoR, DCR, PFS, OS), pharmacokinetics, pharmacodynamics
- Study Duration
- Approximately 18 months
What is AZD8421?
AZD8421 is a new drug currently being studied for its potential in treating certain types of advanced cancers. It is classified as a CDK2 inhibitor, which means it targets a specific protein in cancer cells involved in cell division. This drug is still in the early stages of research and is not yet approved for general use.
Target Conditions
The clinical trial is focusing on two main types of cancer: ER+ HER2- Advanced Breast Cancer: This is a type of breast cancer that is estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-). "Advanced" means the cancer has spread beyond the breast to other parts of the body. High-grade Serous Ovarian Cancer (HGSOC): This is an aggressive form of ovarian cancer that has spread to other parts of the body (metastatic).
How AZD8421 Works
AZD8421 is designed to inhibit CDK2, a protein that plays a crucial role in cell division. By targeting this protein, the drug aims to slow down or stop the growth of cancer cells. This approach is particularly promising for cancers that have become resistant to other treatments.
Clinical Trial Overview
The current study of AZD8421 is a Phase I/IIa clinical trial, which means it's one of the earliest stages of testing in humans. The main goals of this trial are: To evaluate the safety and tolerability of AZD8421 To determine the best dose for future studies To assess how the drug behaves in the body (pharmacokinetics) To look for early signs of effectiveness against cancer
Combination Therapies
The trial is not only testing AZD8421 by itself but also in combination with other cancer drugs: Camizestrant (also known as AZD9833): This is a type of drug called a SERD (Selective Estrogen Receptor Degrader), which targets estrogen receptors in breast cancer cells. CDK4/6 inhibitors: These are drugs that target different proteins involved in cell division. The trial is testing AZD8421 with one or more of the following: Abemaciclib (also known as Verzenios) Ribociclib (also known as Kisqali) Palbociclib (also known as Ibrance)
Safety and Efficacy Measures
The researchers are closely monitoring several aspects to ensure patient safety and evaluate the drug's effectiveness: Side effects and serious adverse events Changes in laboratory tests, vital signs, and heart activity (ECGs) How well tumors respond to the treatment (e.g., if they shrink or stop growing) How long patients live without their cancer getting worse (progression-free survival) Overall survival rates
Pharmacokinetics
The study is also looking at how AZD8421 behaves in the body, including: How quickly the drug reaches its maximum concentration in the blood How long it stays in the body How the body processes and eliminates the drug This information helps researchers understand how to best administer the drug for maximum effectiveness and safety.
Potential Benefits
While it's too early to know for sure, researchers hope that AZD8421 might offer several potential benefits: A new treatment option for patients whose cancer has become resistant to other therapies Possible improved outcomes when combined with existing cancer drugs A targeted approach that may have fewer side effects than traditional chemotherapy It's important to remember that as this is an early-stage trial, more research will be needed to fully understand the benefits and risks of AZD8421.